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Background: Microbiological diagnosis of aspergillosis and triazole resistance is limited
by poor culture yield. To better estimate this shortcoming, we compared culture and
molecular detection of A. fumigatus in respiratory samples from French patients at risk
for aspergillosis.
Methods: A total of 97 respiratory samples including bronchoalveolar lavages (BAL),
bronchial aspirates (BA), tracheal aspirates, sputa, pleural fluids, and lung biopsy were
collected from 33 patients having invasive aspergillosis (n = 12), chronic pulmonary
aspergillosis (n = 3), allergic bronchopulmonary aspergillosis (n = 7), or colonization
(n = 11) and 28 controls. Each specimen was evaluated by culture, pan-Aspergillus
qPCR, and CYP51A PCR and sequencing.
Results: One A. flavus and 19 A. fumigatus with one multiazole resistant strain (5.3%)
were cultured from 20 samples. Culture positivity was 62.5, 75, 42.9, and 15.8% in ABPA,
CPA, IA, and colonized patients, respectively. Aspergillus detection rate was significantly
higher by pan-Aspergillus qPCR than by culture in IA (90.5 vs. 42.9%; P < 0.05) and
colonization group (73.7 vs. 15.8%; P < 0.05). The CYP51A PCR found one TR34/L98H
along with 5 novel cyp51A mutations (4 non-synonymous and 1 promoter mutations),
yet no association can be established currently between these novel mutations and azole
resistance. The analysis of 11 matched pairs of BA and BAL samples found that 9/11
BA carried greater fungal load than BAL and CYP51A detection was more sensitive in
BA than in BAL.
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Conclusion: Direct molecular detection of Aspergillus spp. and azole resistance
markers are useful adjunct tools for comprehensive aspergillosis diagnosis. The
observed superior diagnostic value of BAs to BAL fluids warrants more in-depth
study.
Keywords: Aspergillus fumigatus, azole resistance, respiratory samples, French patients, CYP51A, molecular
diagnostics
INTRODUCTION
Aspergillus spp., especially Aspergillus fumigatus, are the main
causes of a wide spectrum of diseases including invasive
aspergillosis (IA), chronic pulmonary aspergillosis and allergic
syndromes. Highly active triazoles except fluconazole are
recommended as the first-line therapy to treat aspergillosis,
but their effectiveness is challenged by the emergence of drug
resistance (Verweij et al., 2015; Denning et al., 2016). Since the
late 2000s, when two distinct routes of resistance development
(environmental exposure to azole fungicides and long-term
azole therapy) were reported (Verweij et al., 2007; Howard
et al., 2009), a number of national or local hospital/medical
center-based surveys have been carried out to assess local
or regional epidemiology of azole resistance in A. fumigatus
(Lockhart et al., 2011; Chowdhary et al., 2015; Van Der Linden
et al., 2015; Vermeulen et al., 2015; Le Pape et al., 2016).
These epidemiological studies revealed striking variance on
the prevalence of resistance in different geographical areas or
subpopulations, for example, a recent national survey in the
Netherlands reported that azole resistance rates at the hospital
level varied between 5 and 10%, although rates up to 30%
were reported in high-risk wards (Lestrade et al., 2016). One
problem with assessing prevalence of resistance is noted as the
recovery of A. fumigatus in culture is generally low and may
vary considerably among different patient groups. This outcome
indicates that in culture-negative patients, the presence of azole
resistance will be missed (Van Der Linden et al., 2016).
In fact, A. fumigatus is notorious for its low culturability from
infection sites, especially in chronic infection patients as well as
neutropenic IA patients (Denning et al., 2011; Bergeron et al.,
2012). By using a highly sensitive and specific PCR method,
it was previously shown that the resistance-associated cyp51A
mutation was found in as high as 55% of non-culturable but
Aspergillus PCR positive respiratory samples (Denning et al.,
2011). Although such high resistance rate was not observed
in subsequent studies from different patient populations, direct
detection of A. fumigatus and azole resistance markers from
bronchoalveolar lavage (BAL) fluid did demonstrate cryptic azole
resistance that may be missed by culture-based diagnosis (Zhao
et al., 2013).
In France, both high and low prevalence of azole resistance in
A. fumigatus clinical isolates have been reported from different
populations and locations (Alanio et al., 2011, 2016; Burgel et al.,
2012; Morio et al., 2012; Choukri et al., 2015), but no study has
assessed diagnostic value of direct detection of Aspergillus spp.
and azole resistancemarker from primary samples in populations
at high risk for Aspergillus infections. Herein, we compared
diagnostic performance of culture and molecular detection of
Aspergillus spp. andA. fumigatusCYP51A profiling in respiratory
samples from patients with various underlying diseases at one
medical center in France.
MATERIALS AND METHODS
Patient Characteristics and Sample
Collection
A total of 97 respiratory samples (including BAL, BA, tracheal
aspirates, sputa, pleural fluids, and lung biopsy) from 33 patients
and 28 controls collected at the Grenoble Alpes University
Hospital in Grenoble, France, between October 2013 and July
2014 were included in the study. Allergic bronchopulmonary
aspergillosis (ABPA), chronic pulmonary aspergillosis (CPA),
and IA were defined in accordance with the classifications
established by the international committees of experts available
at the time of the study (Denning et al., 2003; Stevens et al., 2003;
De Pauw et al., 2008; Smith and Denning, 2011; Garnaud et al.,
2012; Agarwal et al., 2013; Schweer et al., 2014). Colonization
was defined as a culture (or a previous history) that yielded
Aspergillus spp. from respiratory specimens in patients who did
not match the criteria for IA, CPA or ABPA diagnosis and had
no major respiratory symptoms. Control patients were defined
as having pulmonary symptoms and in whom the diagnosis
of Aspergillus infection or colonization was ruled out. The
underlying diseases are listed in Table 1. All specimens were
aliquoted upon collection in a biosafety cabinet and subjected to
culture on Sabouraud-Chloramphenicol tubes and Candida ID2
plates (bioMérieux, Marcy l’Étoile, France), pan-Aspergillus real-
time PCR, and CYP51A PCR and sequencing. Aliquots for PCR
testing were stored frozen at −80◦C until process. According to
the clinical evaluation and the requests from the physician, 18
samples from 13 patients (3 controls, 1 colonization, 1 CPA, and
8 IA) were also tested for galactomannan (GM)with the Platelia R©
Aspergillus assay (BioRad, Marnes-la-Coquette, France).
Susceptibility Testing
Following species identification, all A. fumigatus isolates were
assessed by Etest R© (bioMérieux) and the resistant isolate was
subjected to microdilution susceptibility testing for itraconazole,
voriconazole and posaconazole following the Clinical Laboratory
and Standards Institute protocol M38-A2 (CLSI, 2008).
DNA Extraction and CYP51A Profiling
Excluding sputa and one lung biopsy, all fluid samples
(1ml when available, otherwise the entire volume) were
centrifuged at 16000 g for 10min at 4◦C. Pellets, sputum and
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TABLE 1 | Underlying conditions of the patients and controls.
Clinical diagnosis No. of patients (no. of specimens) with underlying conditions Total
CF CF + SOT SOT HAEM PULM Other
ABPA 6 (6) 0 0 0 1 (2) 0 7 (8)
CPA 0 0 1 (1) 0 2 (3) 0 3 (4)
IA 1 (1) 0 1 (2) 7 (15) 2 (2) 1 (1) 12 (21)
Colonization 1 (1) 2 (5) 5 (8) 2 (4) 1 (1) 0 11 (19)
Control 3 (4) 1 (1) 6 (11) 7 (11) 11 (18) 0 28 (45)
Total 11 (12) 3 (6) 13 (22) 16 (30) 17 (26) 1 (1) 61 (97)
CF, cystic fibrosis; SOT, solid organ transplantation; HAEM, hematological malignancies;PULM, pulmonary disorders other than CF; Other, digestive surgery.
TABLE 2 | Culture, pan-Aspergillus PCR, and CYP51A PCR detection in different patient groups.
Clinical diagnosis Culture pan-Aspergillus PCR CYP51A PCR
Aspergillus spp.a Non-Aspergillus spp. neg. Total (%)e Pos. Neg. Total (%) Pos. Neg. Total (%)
ABPA 5 1b 2 8 (62.5) 6 2 8 (75) 6 2 8 (75)
CPA 3 0 1 4 (75) 4 0 4 (100) 4 0 4 (100)
IA 9 0 12 21 (42.9) 19 2 21 (90.5)f 16 5 21 (76.2)
Colonization 3 1c 15 19 (15.8) 14 5 19 (73.7)f 12 7 19 (63.2)
Control 0 2d 43 45 1 44 45 (2.2) 0 45 45
Total 20 4 73 97 44 53 97 38 59 97
aExcept one isolate from an IA patient is A. flavus, all isolates are A. fumigatus.
bScedosporium spp.
cPenicillium spp.
dNon-Aspergillus spp. include 1 Exophiala spp., and 1 Penicillium spp.
e% is Aspergillus spp. culture positivity.
fPCR detection positivity significantly higher than culture, P = 0.0025 for IA group, and P = 0.0008 for colonization group.
lung biopsy samples were processed with DNA extraction,
using MasterPureTM Yeast DNA Purification kit (Epicentre
Biotechnologies, Madison, WI, USA), as described previously
(Zhao et al., 2013). A pan-Aspergillus real-time PCR along with
nested PCR amplification of the A. fumigatus CYP51A ORF and
promoter region, and DNA sequencing of PCR amplicons were
performed blinded on all samples, as described previously (Zhao
et al., 2013).
Statistical Analysis
Fisher’s exact test was used to compare detection rate of culture
and PCR. A P < 0.05 was considered statistically significant.
Ethics Statement
This study was approved by Rutgers Health Sciences Institutional
Review Board (IRB).
RESULTS
Detection of Aspergillus spp. from
Respiratory Samples
A total of 20 samples (7 BA, 2 BAL, 9 sputa, and 2 tracheal
aspirates) were culture positive for Aspergillus spp., including
19 A. fumigatus and 1 A. flavus. Aspergillus culture positivity
was 62.5, 75, 42.9, and 15.8% in samples from ABPA, CPA, IA,
and colonized patients, respectively. No Aspergillus was isolated
from control samples, but one sample was culture-positive for
Exophiala spp. and one was culture-positive for Penicillium spp.
(Table 2). In comparison, Aspergillus detection rate was generally
higher in all patient groups by pan-Aspergillus real-time PCR
than by culture. In particular, PCR positivity was significantly
higher than culture positivity in the IA group (90.5 vs. 42.9%; P <
0.05). The same significant difference was observed in the group
of colonized patients (73.7 vs. 15.8%; P < 0.05). Only 1/45 (2.2%)
control samples were pan-Aspergillus PCR positive. Among 18
specimens (8 BAL, 5 BA, 2 tracheal aspirate, 1 pleural fluid, 1
sputum, and 1 lung biopsy) available for GM evaluation, 10/11
GM-positive and 2/7 GM-negative samples were pan-Aspergillus
PCR positive with culture-positive for one A. fumigatus and one
A. flavus.
Azole Resistance Profile
According to susceptibility testing results, allA. fumigatus isolates
were susceptible to all three tested azole drugs except one
from a colonized patient demonstrating a multiazole resistant
pattern (MIC results itraconazole 16mg/L; posaconazole 1mg/L;
voriconazole 4mg/L). This patient received daily posaconazole
(800mg/d) treatment for one year prior to the sampling. The
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resistance rate estimated from A. fumigatus culture was 1/19
(5.3%). When A. fumigatus CYP51A PCR was applied directly
to respiratory samples, 38 of 44 pan-Aspergillus PCR positive
samples were successfully amplified. Among the six samples that
failed to amplify in CYP51A PCR, one was A. flavus culture-
positive, one was Penicillium culture-positive, and another
culture-negative sample was positive in species-specific real-time
PCR for A. flavus but not A. fumigatus (data not shown). The
remaining 3 pan-Aspergillus PCR positive but CYP51A PCR
negative samples had Ct values of 34.3, 34.8, and 35.9 in pan-
Aspergillus detection, respectively, suggesting a low amount of
Aspergillus DNA in these samples. Non-synonymous mutations
(Table 3) were observed in 5/38 (13.2%) CYP51A PCR positive
samples, and 3 of which were from culture negative specimens.
Except for one TR34/L98H found in a sputum sample that
was culture-positive with the multiazole resistant profile, other
mutations causing amino acid substitutions in the cyp51A
protein were novel. In addition to the patient with the TR34/L98H
mutation, previous azole therapy was found in two other patients
showing CYP51A mutated Aspergillus (Table 3).
Respiratory Sample Type Impact on
Aspergillus Detection
To investigate the diagnostic value of different respiratory sample
types for both Aspergillus and azole resistance detection, we
analyzed 11 matched pairs of BAL and bronchial aspirate (BA)
samples collected during the same bronchoscopy exam, from 11
patients with different underlying diseases and clinical diagnosis
(Table 4). Interestingly, 9 out of 11 BA samples (from patient A to
I) had an average of 4.7 lower pan-Aspergillus Ct value than their
matched BAL samples, indicating a greater load of Aspergillus in
BA than in BAL, regardless of underlying diseases or infection
status. In particular, while robust signals were detected in BAs
from patient A and patient I, matched BAL fluids from these
two patients failed to generate positive amplicon signals. As a
consequence of such Aspergillus load difference, while CYP51A
sequence was available from both sample types for four patients
(patients B, G, H, and J), in six patients (patients A, C, D, E,
F, and I) it was only detectable from BA samples. Two non-
synonymous CYP51A mutations were found, one (I217T) was in
the BAL fluid from patient B, and the other (L399F) was in the
BA from patient D. Patient J had very close Aspergillus burden
measurement [1Ct(BAL−BA) = −0.6] in the matched set of BA
and BAL, but only the BA was culture positive for a susceptible
A. fumigatus. The only exception to the general observation
that BA tends to have greater fungal load resulting in higher
Aspergillus and resistance marker detection positivity was patient
K, who had a positive pan-Aspergillus PCR result with a Ct of
34.1, as well as positive CYP51A PCR detection, in his BAL, but
the matched BA was negative in all tests. Regarding the culture
results, no difference could be drawn between BAL and BA expect
for patient J.
DISCUSSION
We have previously demonstrated the use of pan-Aspergillus
PCR to uncover non-culturable A. fumigatus from respiratory
samples (Denning and Perlin, 2011; Zhao et al., 2013).
Consistently, in the present study application of pan-Aspergillus
PCR resulted in higher detection rate than culture in all patient
groups, particularly IA and colonized patients. Previously,
the relatively high positivity (>30%) of Aspergillus PCR in
control group (normal healthy volunteer or GM-negative BAL)
was seen with small number of control samples in both
studies. Therefore, we have increased the number of control
samples in the current study, where 45/97 (46.4%) samples are
considered as “Aspergillus-free” according to clinical diagnosis
and microbiological laboratory tests. Except one positive result
from one Penicillium culture-positive sample expected due to
the cross-activity with Penicillium spp. of the assay, the PCR
positivity in control group was 1/45 (2.2%) demonstrating
excellent specificity of the test. This result further supports the
notion of implementing PCR to facilitate rapid diagnosis of
Aspergillus infections.
TABLE 3 | A. fumigatus CYP51A mutations detected directly from respiratory samples.
Specimen Patient category Clinical diagnosis Culture/azole susceptibility Mutations* Prior azole therapy dosage and duration
Sputum SOT Colonization A. fumigatus/ITC = 16 mg/L,
POS =1 mg/L, VRC = 4 mg/L
TR34/L98H POS 800 mg/d for 1 year
BAL SOT Colonization Negative I217T No
BA HAEM Colonization Negative R355H No
BA HAEM Colonization Negative L399F No
Sputum CF ABPA A. fumigatus/susceptible I354V No
BA PULM CPA A. fumigatus/susceptible promoter -129 T to C VRC 400 mg/d for 3 months until 3 months
before sampling
BAL HAEM IA Negative D70D; T140T No
BA HAEM IA Negative L77L No
BA PULM ABPA Negative R65R No
BAL SOT Control Negative E356E VRC 400 mg/d for 2 years
ITC, itraconazole; POS, posaconazole; VRC, voriconazole.
* Non-synonymous mutations are bolded.
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TABLE 4 | Aspergillus and azole resistance profile in matched pairs of BA and BAL samples.
Patient Specimen Underlying Clinical Culture/azole Pan-Aspergillus Ct 1Ct (BAL−BA)* CYP51A PCR Mutations
disease diagnosis susceptibility PCR
A BA CF+SOT Colonization Negative Pos. 31.8 Pos. None
BAL CF+SOT Colonization Negative Neg. No Ct 8.2 Neg. NA
B BA SOT Colonization Negative Pos. 31.7 Pos. None
BAL SOT Colonization Negative Pos. 33.4 1.7 Pos. I217T
C BA HAEM IA Negative Pos. 28.4 Pos. None
BAL HAEM IA Negative Pos. 35.9 7.5 Neg. NA
D BA HAEM Colonization Negative Pos. 33.4 Pos. L399F
BAL HAEM Colonization Negative Neg. 36.2 2.8 Neg. NA
E BA CF+SOT Colonization Penicillium spp. Pos. 30.6 Pos. None
BAL CF+SOT Colonization Negative Pos. 34.8 4.2 Neg. NA
F BA SOT Colonization Negative Pos. 33.9 Pos. None
BAL SOT colonization Negative Neg. 36.2 2.3 Neg. NA
G BA SOT IA A. fumigatus/susceptible Pos. 24.9 Pos. None
BAL SOT IA A. fumigatus/susceptible Pos. 27.1 2.3 Pos. None
H BA HAEM IA A. fumigatus/susceptible Pos. 29.6 Pos. None
BAL HAEM IA A. fumigatus/susceptible Pos. 34.4 4.9 Pos. None
I BA PULM ABPA Negative Pos. 31.4 Pos. R65R
BAL PULM ABPA Negative Neg. No Ct 8.7 Neg. NA
J BA HAEM IA A. fumigatus/susceptible Pos. 32.4 Pos. None
BAL HAEM IA Negative Pos. 31.8 −0.6 Pos. None
K BA HAEM IA Negative Neg. No Ct Neg. NA
BAL HAEM IA Negative Pos. 34.1 −5.9 Pos. None
NA, not applicable.
* A Ct-value of 40 was used to calculate Ct difference between BA and BAL samples when no Ct was reported for pan-Aspergillus PCR.
BAL fluid is the most commonly used respiratory sample
type for the diagnosis of aspergillosis (Nguyen et al., 2007;
Johnson et al., 2015). Yet, the diagnostic value of other respiratory
sample types has not been fully defined. In the present study,
BAL samples were collected from the distal pulmonary tract
following instillation of a large volume of saline, about 100ml
in three aliquots. Bronchial aspirates were performed during
the same bronchoscopy before BAL and after the end of BAL
collection. Therefore, compared to BAL, BA is much less diluted
and contain more mucous. In this study, we analyzed 11
matched pairs of BA and BAL samples from 11 patients with
different underlying diseases and clinical diagnosis. Interestingly,
a significantly higher Aspergillus load and resistance marker
detection rate were observed in the majority of BAs than in
their matched BALs. This result is consistent with two recent
reports, where respiratory samples (bronchial wash or bronchial
secretion) collected in a similar way demonstrated equal or even
higher diagnostic yield compared to BAL fluids (Escribano et al.,
2015; Taremi et al., 2015). In addition, it confirms a previous
French study, which already suggested the superiority of the BA
in the setting of IA diagnosis in hematological patients (Bergeron
et al., 2012).
Although the prevalence of azole resistance in A. fumigatus
has been investigated recently in diverse populations in France
(Alanio et al., 2011, 2016; Burgel et al., 2012; Morio et al., 2012;
Choukri et al., 2015), the true frequency of resistance remains
largely unknown due to following reasons. First, the prevalence
reported from previous studies was based on susceptibility testing
of clinical A. fumigatus isolates, representing <50% of infections
caused by this organism, even in confirmed aspergillosis cases
(Reichenberger et al., 1999; Nguyen et al., 2011; Arendrup
et al., 2012). Therefore, the presence of azole resistance in
non-culturable A. fumigatus was missed by the culture-based
assessment. Second, no permanent surveillance system based on
sensitive Aspergillus azole resistance detection methods exist in
France and the prevalence of resistance may differ considerably
from each other depending on location of studied hospitals and
patients’ underlying diseases (Alanio et al., 2016), hence data
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obtained from certain sub-populations may not be representative
for other populations with different underlying diseases or from
different geographical areas. In the present study 5.3% (1/19) of
A. fumigatus isolates displayed an azole resistance phenotype,
lower than 8% in one CF population (Morio et al., 2012) but
higher than 1.1% in hematological patients or 1.8% in unselected
patients in France (Alanio et al., 2011). Considering the mixed
composition of patients in the current study, this result was
somewhat expected, and also supports the comment made by van
der Linden et al. about the need to determine azole resistance
frequency at the hospital level and within different patient groups
(Van Der Linden et al., 2016).
In the present study, direct CYP51A detection enabled
azole resistance profiling in 19 non-culturable or A. fumigatus
culture-negative specimens in addition to other 19 A. fumigatus
culture-positive samples, and one TR34/L98H along with 5
novel cyp51A mutations (4 non-synonymous mutations and 1
promotermutation) were identified. Among the novelmutations,
the I217T alteration detected from a culture-negative BAL may
be of note, because previous work on three-dimension model of
14α-demethylase and related deduction has indicated that I217
is predicted to have direct interactions with either the substrate
or triazole antifungal drugs (Ji et al., 2000; Mellado et al., 2004).
Other novel mutations could possibly be natural polymorphisms.
Nevertheless, whether or not these mutations are associated
with azole resistance needs further evaluation. Compared to our
previous findings in the UK patient population (Denning et al.,
2011), direct CYP51A profiling has limited additive value to
azole resistance diagnosis, which is largely due to the very low
resistance rate in this particular population. No clear relation
between prior azole exposure and cyp51A mutation could be
determined from our study since only three patients (out of
the 10 harboring mutated cyp51A) had received azole therapy
before. The patient who had the typical environment-acquired
TR34/L98H detected was treated with posaconazole for a year
prior to sampling, therefore, it is difficult to tell the source of this
mutation in this particular patient.
In summary, our study confirmed the advantage of molecular
methods over culture on diagnosis of aspergillosis. Direct
detection of CYP51A from primary samples is a faster and
reliable azole resistance diagnostic method especially for culture
negative samples, although its value may have been limited in this
particular patient population with very low resistance rate. The
observed superior diagnostic value of BA to BAL fluids warrants
additional in-depth studies.
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